capmatinib hydrochloride · Novartis Pharm · NDA 213591
Tabrecta
Earliest generic entry, as listed · earliest of 2 marketed strengths
22 Jul 2035
Blocked by patent: US 10596178, US 12208101.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10596178 | product | 22 Jul 2035 |
| US 12208101 | product | 22 Jul 2035 |
| US 7767675 | substance, product | 19 Nov 2032 |
| US 8420645 | substance, product | 5 Jun 2031 |
| US 8901123 | use U-2813 | 20 May 2029 |
| US 12084449 | use U-2813 | 19 Nov 2027 |
| US 8461330 | substance, product | 19 Nov 2027 |
Exclusivities · 1 unexpired
| ODE-291 | orphan drug (7 years) | 6 May 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213591 · 001 · RLD | tablet, oral | EQ 150MG BASE | 22 Jul 2035 |
| 213591 · 002 · RLD | tablet, oral | EQ 200MG BASE | 22 Jul 2035 |